In 2012, Bates et al.[150] retrospectively analyzed CRC tumor samples from the phase III bevacizumab E3200 trial to explore the predictive value on treatment outcomes of VEGF165b, a VEGF splice isoform. This evidence concerns the gene VEGFA and neoplasm.